Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
LenstoLensChina's Top Procuratorate Promotes Law's ImplementationConsumption Boom Continues on Mother's Day WeekendChina to Provide Trainee Jobs for College Graduates, Young PeopleChina Focus: PLA Navy's Founding Anniversary Commemorated with Public CelebrationsOrgans Safeguard Campus SecurityMaternity Insurance Coverage to Be ExpandedWater festival attacks kill 3 during Myanmar coup leader’s holiday — Radio Free AsiaChina Makes Great Progress in Combating Trafficking in Women and Children: ExpertChinese Courts Empowered to Better Support Family Education, Protect Minors
3.4427s , 6499.8984375 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,International Informer news portal